Aditxt Subsidiary Pearsanta Begins Enrollment in First Human Study of Blood-Based Diagnostic for Endometriosis, a Condition Affecting 190 Million Women Worldwide and Representing a $1.45 Billion Global Market
Aditxt, Inc. (Nasdaq: ADTX) ('Aditxt' or the 'Company'), a social innovation platform accelerating promising health innovations, today announced that its subsidiary, Pearsanta, Inc. ('Pearsanta...